This will instill confidence in the treating physician and help the administrators to take decisions regarding vaccine procurement and supply logistics. adverse reactions. The rabies computer virus neutralizing antibody titers was assessed by quick fluorescent focus inhibition test and all the vaccinees experienced titers 0.5 IU per mL on day 14 which is considered as adequate for protection against rabies. Thus, the present study showed that, rabies post-exposure prophylaxis was safe and immunogenic despite changes in the route of administration and brand/type of rabies vaccine. value 0.01 Open in a individual window All the study subjects were healthy and alive after 6 mo of completing PEP. Group 2 Among the 43 animal bite victims, who experienced changes in type/ brand of vaccine (27 from PCEC: Rabipur to PVRV: Indirab and Abhayrab and 16 from PVRV: Indirab and Abhayrab to PCEC: Rabipur), 27 were males and 16 females. The age distribution ranged from 15 to 65 y with the mean age of 32.4 y. Majority (60.5%) of doggie bites were unprovoked, around the limbs (83.7%) and all were category III exposures. Wound wash was carried out and all the study subjects received total quantity of required ERIG Mupirocin (Equirab) locally, into, and around the wound/s (Table 1). None of the study subjects reported any adverse drug reactions either to rabies vaccine or ERIG. The RVNA titers of all the vaccinees were 0.5 IU/mL on day 14, IL20RB antibody with the geometric mean concentration (GMC) of 11.84 IU/mL and the range of 7.5C15.5 IU/mL. (Table 2). All the study subjects were healthy and alive after 6 mo of completing PEP. Discussion CCEEVs have been administered to millions of people worldwide and have proved to be safe and effective in preventing rabies. But, there are various issues in PEP especially in developing countries, such as: cost of rabies vaccines, purchase and supply of vaccines to the Government hospitals/ health centers, availability of vaccine stocks, and long course of vaccination. These factors come in the way of administering the same brand/ type and also route of vaccination. Therefore, in the course of PEP, many people cannot accept the entire treatment in the same hospital. Consequently, Mupirocin changes in the route of administration and replacing different vaccine happens. All CCEEVs consist of inactivated rabies computer virus, that has been propagated in different cell substrates and the antigen is usually same in all these vaccines. Furthermore, all CCEEVs induce a prompt and high rabies-virus neutralizing Mupirocin antibody (RVNA) response to the viral G protein as per WHO speci?ed minimum titer of 0.5 IU/mL of serum, as measured by the rapid ?uorescent focus inhibition test (RFFIT) which indicates adequate seroconversion. Hence, an indirect assessment of vaccine efficacy can be made through immunogenicity studies. In healthy vaccinees, this level should be achieved in most of the individuals by day 14 of a post-exposure regimen, with or without simultaneous administration of RIG and irrespective of age.3 In India, where rabies is endemic, 4 types of rabies vaccines are available. The first 3 are the cell Mupirocin culture derived i.e., human diploid cell culture vaccine (HDCV), purified chick embryo cell vaccine (PCECV), and purified vero cell rabies vaccine (PVRV), and the fourth is the purified duck embryo vaccine (PDEV). Similarly, 2 brands of PCEC (Rabipur and Vaxirab N) and 3 brands of PVRV (Verorab, Abhayrab, and Indirab) are marketed in India. All these vaccines have been found to be highly immunogenic, safe, Mupirocin and efficacious.7-9 These vaccines are produced using approved strains of rabies viruses and are released after demanding quality control testing from National drug authorities. Currently the vaccine strains used are PV 11,.